biotech / news / / Devdiscourse
Danish drugmaker LEO Pharma has agreed to acquire U.S. developer Replay for $50 million.
LEO Pharma is acquiring Replay for $50 million to access experimental genetic skin disease treatments.
KEY POINTS
- The FDA has proposed new restrictions on mass compounding of Novo and Lilly's weight-loss drugs.
- A second generic version of Ozempic has been approved in Canada, increasing market competition.
- Cigna will exit the U.S. Obamacare exchange market, consistent with its updated profit projections.
COMPANIES
Summarized by Newsio from Devdiscourse. How we summarize →